Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch
MORRIS PLAINS, N.J., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.69, +0.12, +3.36%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 -- 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).
Posted using ShareThis
No comments:
Post a Comment